AAPL333.02+3.62 (+1.10%) ▲|ABBV261.59-1.70 (-0.65%) ▼|ABT98.83-2.12 (-2.10%) ▼|ACN183.37+6.25 (+3.53%) ▲|ADBE239.94+6.77 (+2.90%) ▲|AMAT511.38-0.63 (-0.12%) ▼|AMD611.76+4.19 (+0.69%) ▲|AMGN421.51-2.13 (-0.50%) ▼|AMT163.69-1.87 (-1.13%) ▼|AMZN249.15+2.48 (+1.01%) ▲|AVGO351.19-3.91 (-1.10%) ▼|AXP304.10-1.30 (-0.43%) ▼|BA186.05-1.63 (-0.87%) ▼|BAC54.43-0.53 (-0.96%) ▼|BKNG162.91+0.57 (+0.35%) ▲|BLK1,058.29-9.65 (-0.90%) ▼|BMY62.40-0.46 (-0.73%) ▼|BNY144.63-2.35 (-1.60%) ▼|BRK-B497.95-4.40 (-0.88%) ▼|C129.48-1.32 (-1.01%) ▼|CAT810.79-15.85 (-1.92%) ▼|CL85.32-1.14 (-1.32%) ▼|CMCSA21.76+0.16 (+0.74%) ▲|COF193.07-3.39 (-1.73%) ▼|COP125.15-0.29 (-0.23%) ▼|COST910.34-14.25 (-1.54%) ▼|CRM229.57+4.26 (+1.89%) ▲|CSCO107.63+0.69 (+0.65%) ▲|CVS85.69-1.41 (-1.62%) ▼|CVX204.21-0.17 (-0.08%) ▼|DE671.55-7.33 (-1.08%) ▼|DHR221.55-4.16 (-1.84%) ▼|DIS104.90-0.51 (-0.48%) ▼|DUK114.01-0.20 (-0.18%) ▼|EMR155.10-2.14 (-1.36%) ▼|FDX285.09-2.38 (-0.83%) ▼|GD331.83-0.51 (-0.15%) ▼|GE312.29-5.60 (-1.76%) ▼|GEV950.49-12.00 (-1.25%) ▼|GILD149.05-2.23 (-1.47%) ▼|GM77.00-3.47 (-4.31%) ▼|GOOG340.74+3.42 (+1.01%) ▲|GOOGL344.08+3.16 (+0.93%) ▲|GS900.36-15.88 (-1.73%) ▼|HD284.49-3.55 (-1.23%) ▼|HON210.94+0.81 (+0.39%) ▲|IBM219.93-0.06 (-0.03%) ▼|INTC120.23+4.30 (+3.71%) ▲|INTU275.71+7.68 (+2.87%) ▲|ISRG406.63-5.55 (-1.35%) ▼|JNJ264.74-2.83 (-1.06%) ▼|JPM330.83-4.15 (-1.24%) ▼|KO86.08-0.76 (-0.88%) ▼|LIN474.65+1.28 (+0.27%) ▲|LLY1,157.08-27.55 (-2.33%) ▼|LMT509.25-2.96 (-0.58%) ▼|LOW184.29-2.97 (-1.59%) ▼|LRCX328.51+4.65 (+1.44%) ▲|MA551.47-12.11 (-2.15%) ▼|MCD230.94-3.04 (-1.30%) ▼|MDLZ57.82-0.98 (-1.67%) ▼|MDT86.29-0.80 (-0.92%) ▼|META725.18-13.61 (-1.84%) ▼|MMM164.15-4.34 (-2.58%) ▼|MO67.34-1.38 (-2.01%) ▼|MRK145.31-3.97 (-2.66%) ▼|MS188.08-4.68 (-2.43%) ▼|MSFT512.90+3.94 (+0.77%) ▲|MU1,065.11+0.03 (+0.00%) ▲|NEE75.74-0.15 (-0.20%) ▼|NFLX69.58-0.72 (-1.02%) ▼|NKE35.40-0.44 (-1.23%) ▼|NOW134.01+4.07 (+3.13%) ▲|NVDA228.38+1.17 (+0.51%) ▲|ORCL137.30-0.49 (-0.36%) ▼|PEP126.72-1.97 (-1.53%) ▼|PFE28.52-0.20 (-0.70%) ▼|PG145.28-3.04 (-2.05%) ▼|PLTR187.05+0.08 (+0.04%) ▲|PM190.82-3.08 (-1.59%) ▼|QCOM184.04-0.06 (-0.03%) ▼|RTX185.65-1.29 (-0.69%) ▼|SBUX93.96-1.47 (-1.54%) ▼|SCHW97.74-1.36 (-1.37%) ▼|SO82.89-0.56 (-0.67%) ▼|SPG200.76-3.52 (-1.72%) ▼|T24.40-0.08 (-0.33%) ▼|TMO675.05-4.56 (-0.67%) ▼|TMUS163.08+0.10 (+0.06%) ▲|TSLA354.81+1.97 (+0.56%) ▲|TXN280.09-1.60 (-0.57%) ▼|UBER68.51-0.85 (-1.23%) ▼|UNH367.08-7.86 (-2.10%) ▼|UNP272.13-2.02 (-0.74%) ▼|UPS93.44-0.49 (-0.52%) ▼|USB57.76+0.16 (+0.28%) ▲|V359.33-6.55 (-1.79%) ▼|VZ45.87-0.11 (-0.24%) ▼|WFC80.05-0.43 (-0.53%) ▼|WMT103.92-2.88 (-2.70%) ▼|XOM162.75+1.40 (+0.87%) ▲|AAPL333.02+3.62 (+1.10%) ▲|ABBV261.59-1.70 (-0.65%) ▼|ABT98.83-2.12 (-2.10%) ▼|ACN183.37+6.25 (+3.53%) ▲|ADBE239.94+6.77 (+2.90%) ▲|AMAT511.38-0.63 (-0.12%) ▼|AMD611.76+4.19 (+0.69%) ▲|AMGN421.51-2.13 (-0.50%) ▼|AMT163.69-1.87 (-1.13%) ▼|AMZN249.15+2.48 (+1.01%) ▲|AVGO351.19-3.91 (-1.10%) ▼|AXP304.10-1.30 (-0.43%) ▼|BA186.05-1.63 (-0.87%) ▼|BAC54.43-0.53 (-0.96%) ▼|BKNG162.91+0.57 (+0.35%) ▲|BLK1,058.29-9.65 (-0.90%) ▼|BMY62.40-0.46 (-0.73%) ▼|BNY144.63-2.35 (-1.60%) ▼|BRK-B497.95-4.40 (-0.88%) ▼|C129.48-1.32 (-1.01%) ▼|CAT810.79-15.85 (-1.92%) ▼|CL85.32-1.14 (-1.32%) ▼|CMCSA21.76+0.16 (+0.74%) ▲|COF193.07-3.39 (-1.73%) ▼|COP125.15-0.29 (-0.23%) ▼|COST910.34-14.25 (-1.54%) ▼|CRM229.57+4.26 (+1.89%) ▲|CSCO107.63+0.69 (+0.65%) ▲|CVS85.69-1.41 (-1.62%) ▼|CVX204.21-0.17 (-0.08%) ▼|DE671.55-7.33 (-1.08%) ▼|DHR221.55-4.16 (-1.84%) ▼|DIS104.90-0.51 (-0.48%) ▼|DUK114.01-0.20 (-0.18%) ▼|EMR155.10-2.14 (-1.36%) ▼|FDX285.09-2.38 (-0.83%) ▼|GD331.83-0.51 (-0.15%) ▼|GE312.29-5.60 (-1.76%) ▼|GEV950.49-12.00 (-1.25%) ▼|GILD149.05-2.23 (-1.47%) ▼|GM77.00-3.47 (-4.31%) ▼|GOOG340.74+3.42 (+1.01%) ▲|GOOGL344.08+3.16 (+0.93%) ▲|GS900.36-15.88 (-1.73%) ▼|HD284.49-3.55 (-1.23%) ▼|HON210.94+0.81 (+0.39%) ▲|IBM219.93-0.06 (-0.03%) ▼|INTC120.23+4.30 (+3.71%) ▲|INTU275.71+7.68 (+2.87%) ▲|ISRG406.63-5.55 (-1.35%) ▼|JNJ264.74-2.83 (-1.06%) ▼|JPM330.83-4.15 (-1.24%) ▼|KO86.08-0.76 (-0.88%) ▼|LIN474.65+1.28 (+0.27%) ▲|LLY1,157.08-27.55 (-2.33%) ▼|LMT509.25-2.96 (-0.58%) ▼|LOW184.29-2.97 (-1.59%) ▼|LRCX328.51+4.65 (+1.44%) ▲|MA551.47-12.11 (-2.15%) ▼|MCD230.94-3.04 (-1.30%) ▼|MDLZ57.82-0.98 (-1.67%) ▼|MDT86.29-0.80 (-0.92%) ▼|META725.18-13.61 (-1.84%) ▼|MMM164.15-4.34 (-2.58%) ▼|MO67.34-1.38 (-2.01%) ▼|MRK145.31-3.97 (-2.66%) ▼|MS188.08-4.68 (-2.43%) ▼|MSFT512.90+3.94 (+0.77%) ▲|MU1,065.11+0.03 (+0.00%) ▲|NEE75.74-0.15 (-0.20%) ▼|NFLX69.58-0.72 (-1.02%) ▼|NKE35.40-0.44 (-1.23%) ▼|NOW134.01+4.07 (+3.13%) ▲|NVDA228.38+1.17 (+0.51%) ▲|ORCL137.30-0.49 (-0.36%) ▼|PEP126.72-1.97 (-1.53%) ▼|PFE28.52-0.20 (-0.70%) ▼|PG145.28-3.04 (-2.05%) ▼|PLTR187.05+0.08 (+0.04%) ▲|PM190.82-3.08 (-1.59%) ▼|QCOM184.04-0.06 (-0.03%) ▼|RTX185.65-1.29 (-0.69%) ▼|SBUX93.96-1.47 (-1.54%) ▼|SCHW97.74-1.36 (-1.37%) ▼|SO82.89-0.56 (-0.67%) ▼|SPG200.76-3.52 (-1.72%) ▼|T24.40-0.08 (-0.33%) ▼|TMO675.05-4.56 (-0.67%) ▼|TMUS163.08+0.10 (+0.06%) ▲|TSLA354.81+1.97 (+0.56%) ▲|TXN280.09-1.60 (-0.57%) ▼|UBER68.51-0.85 (-1.23%) ▼|UNH367.08-7.86 (-2.10%) ▼|UNP272.13-2.02 (-0.74%) ▼|UPS93.44-0.49 (-0.52%) ▼|USB57.76+0.16 (+0.28%) ▲|V359.33-6.55 (-1.79%) ▼|VZ45.87-0.11 (-0.24%) ▼|WFC80.05-0.43 (-0.53%) ▼|WMT103.92-2.88 (-2.70%) ▼|XOM162.75+1.40 (+0.87%) ▲|
19 C
New York
Thursday, October 1, 2026

Tag: time

newssourceFORcompanyinformationcontent1releasesmarket

[Ad hoc announcement pursuant to Art. 53 LR] Roche provides safety update on Elevidys™ gene therapy for Duchenne muscular dystrophy in non-ambulatory patients

Basel, 15 June 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today new dosing restrictions, effective immediately, for ELEVIDYS™ (delandistrogene moxeparvovec), for non-ambulatory Duchenne muscular dystrophy (DMD) patients, irrespective of age, in both clinical and commercial settings. In the commercial setting, non-ambulatory patients should no longer receive Elevidys. In the clinical trial setting, enrolment and dosing of non-ambulatory patients will be immediately paused until additional risk mitigation measures (e.g. immune modulatory treatment) are implemented in the study protocol. Health authorities, investigators and physicians are being informed so that patient care can be quickly adjusted.

Cheap AI Bots Eye Junior Coders’ Lunch

In 2007, Luke Arrigoni pulled in $63,000 as a junior software developer. Fast forward to today, and AI tools that supposedly churn out better...

ROSEN, GLOBAL INVESTOR COUNSEL, Encourages PepGen Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – PEPG

NEW YORK, June 14, 2025 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of PepGen Inc. (NASDAQ: PEPG) between March 7, 2024 and March 3, 2025, both dates inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than August 8, 2025.

Ready Payday Loans offers Emergency Loans for Bad Credit with No Credit Check

LONG BEACH, Calif., June 14, 2025 (GLOBE NEWSWIRE) -- For individuals facing urgent financial needs, Ready Payday Loans offers fast and reliable access to same-day loans online with no credit check. We are happy to announce our new partnership in June 2025 with lenders across the Nation offering Payday Advance Loans. Whether you're managing medical bills, unexpected car repairs, or late rent, borrowers can now apply for payday loans online same day with instant approval—even if their credit history isn’t perfect. Our streamlined platform connects consumers with reputable lenders who prioritize speed, security, and simplicity. Below is a breakdown of the 5 same day loan partnerships available.

Ram Brand Launches ‘Never Stop Being American’ Marketing Campaign, New Brand Ethos ‘Nothing Stops Ram’

"Never Stop Being American" marketing campaign takes off across broadcast and Ram brand's social media channelsCampaign celebrates America, its people, pastimes and traditions, formally...

Nimanode Surpasses Crypto Presales, Eyes 10X Growth Post-Launch as Major Investors Flock to the XRP DeFi Landscape

LEEDS, United Kingdom, June 14, 2025 (GLOBE NEWSWIRE) -- Nimanode, the first no-code AI agent platform built natively on the XRP Ledger (XRPL), is gaining momentum with its ongoing $NMA token presale.

No KYC. 100x Leverage. $50 Welcome Bonus. Crypto Futures Trading Made Easy on BexBack.

SINGAPORE, June 14, 2025 (GLOBE NEWSWIRE) -- With the price of Bitcoin fluctuating around $100,000, many analysts predict that the cryptocurrency market will remain in a state of high volatility for a long time. Holding spot positions may struggle to generate short-term profits in such conditions. As a result, 100x leverage futures trading has become the preferred tool for seasoned investors looking to maximize potential gains in this volatile market. BexBack Exchange is ramping up its efforts to offer traders unmatched promotional packages. The platform now features a 100% deposit bonus, a $50 welcome bonus for new users, and 100x leverage on cryptocurrency trading, providing exceptional opportunities for investors.

Celldex Presents Data Demonstrating Profound Long Term Improvement in Angioedema in Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI 2025

HAMPTON, N.J., June 14, 2025 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced data demonstrating that barzolvolimab profoundly improves angioedema at 52 weeks in the Company’s Phase 2 clinical trial in chronic spontaneous urticaria (CSU). Angioedema, characterized by swelling of the deeper dermal layers of the skin and mucous membranes, is a painful, debilitating symptom of CSU that has significant impact on quality of life. It commonly affects the face (lips and eyelids), hands, feet, and genitalia but can also involve the tongue, uvula, soft palate, and pharynx1.

Sport Clips Haircuts Hosts National Signing Days

Recruiting Top Styling Talent Ready for the Big Leagues GEORGETOWN, Texas, June 14, 2025 /PRNewswire/ -- Styling professionals looking to take their careers to the next...

Jasper Therapeutics Reports Positive Data from 180mg Cohort in SPOTLIGHT Study of Briquilimab in Chronic Inducible Urticaria

11 of 12 participants (92%) enrolled in the 180mg cohort achieved a complete response

PFMCrypto’s “1-Day Mining Contract” Sales Surge 76% – $1 Million Giveaway Ignites Community Buzz

As PFMCrypto’s AI-driven mining model gains momentum, the platform celebrates a major milestone with a global bonus campaign for new users 
As PFMCrypto’s AI-driven mining model gains momentum, the platform celebrates a major milestone with a global bonus campaign for new users

ROSEN, LEADING INVESTOR COUNSEL, Encourages Iovance Biotherapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – IOVA

NEW YORK, June 14, 2025 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) between May 9, 2024 and May 8, 2025, both dates inclusive (the “Class Period”), of the important July 14, 2025 lead plaintiff deadline.

ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Bitfarms Ltd. Investors to Secure Counsel Before Important Deadline in Securities Class Action – BITF

NEW YORK, June 14, 2025 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Bitfarms Ltd. (NASDAQ: BITF) between March 21, 2023 and December 9, 2024, both dates inclusive (the “Class Period”), of the important July 8, 2025 lead plaintiff deadline.

HSA/FSA Eligible Adjustable Dumbbells & Home Gym Equipment

Save Up to 40% on Core's Space-Saving Home Gym Equipment with HSA/FSA via Truemed(Individual tax rates vary). YOUNGSTOWN, Ohio, June 14, 2025 /PRNewswire/ -- Core...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsTime

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers